LitAlert ~~ GeneLit.com

    • Prognostic and Predictive Biomarkers in Familial Breast Cancer.
    • Deb S, Chakrabarti A, Fox SB.
    • Cancers (Basel). 2023 Feb 20;15(4):1346. doi: 10.3390/cancers15041346.
    • Functional homologous recombination assay on FFPE specimens of advanced high-grade serous ovarian cancer predicts clinical outcomes.
    • Pikkusaari S, Tumiati M, Virtanen A, Oikkonen J, Li Y, Perez-Villatoro F, Muranen T, Salko M, Huhtinen K, Kanerva A, Koskela H, Tapper J, Koivisto-Korander R, Joutsiniemi T, Haltia UMLassus H, Hautaniemi S, Farkkila A, Hynninen J, Hietanen S, Carpén O, Kauppi L.
    • Clin Cancer Res. 2023 Feb 20:ccr.22.3156. doi: 10.1158/1078-0432.CCR-22-3156. Epub ahead of print.
    • A de novo ERBB3 mutation resulted in Olaparib resistance after successful conversion therapy for a GBC patient bearing BRCA1 mutation.
    • Yang JX, Jia ZY, Liu FT, Wu WG, Li XC, Zou L, Li HF, Zhang F, Bao RF, Peng SY, Lau WY, Liu Y, Li ML, Liu YB.
    • Front Oncol. 2023 Feb 20;13:1078388. doi: 10.3389/fonc.2023.1078388.
    • Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report.
    • di Mauro P, Schivardi G, Pedersini R, Laini L, Esposito A, Amoroso V, Laganà M, Grisanti S, Cosentini D, Berruti A.
    • Front Oncol. 2023 Feb 20;13:1139372. doi: 10.3389/fonc.2023.1139372.
    • Exploring the role of a multidisciplinary hereditary gynecologic oncology clinic in epithelial ovarian cancer risk-reducing surgical decision-making practices: A mixed-methods study.
    • Casalino S, Bruce S, Serfas K, Altman AD, Kean S, Lambert P, McManus KJ, Hartley JN, Nachtigal MW.
    • J Genet Couns. 2023 Feb 20. doi: 10.1002/jgc4.1684. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • The Psychosocial Impact of the Decision to Undergo Risk-Reducing Salpingo-Oophorectomy Surgery in BRCA Mutation Carriers and the Role of Physician-Patient Communication.
    • Alves-Nogueira AC, Melo D, Carona C, Figueiredo-Dias M.
    • Curr Oncol. 2023 Feb 18;30(2):2429-2440. doi: 10.3390/curroncol30020185.
    • Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.
    • Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Reda M, Albuisson J, Arnould L, Boidot R, Truntzer C, Ghiringhelli F, Ladoire S.
    • Cancers (Basel). 2023 Feb 17;15(4):1299. doi: 10.3390/cancers15041299.
    • Drugmakers Pushing Frontline PARP Inhibitor Combos for All mCRPC Patients Amid Oncologists' Concerns.
    • Hopkins C.
    • Precision Oncology News. 2023 Feb 17.
    • Press
  • LitAlert ~~ GeneLit.com

    • Potential Impact of PI3K-AKT Signaling Pathway Genes, KLF-14, MDM4, miRNAs 27a, miRNA-196a Genetic Alterations in the Predisposition and Progression of Breast Cancer Patients.
    • Alzahrani OR, Mir R, Alatwi HE, Hawsawi YM, Alharbi AA, Alessa AH, Albalawi ES, Elfaki I, Alalawi Y, Moharam L, El-Ghaiesh SH.
    • Cancers (Basel). 2023 Feb 17;15(4):1281. doi: 10.3390/cancers15041281.
    • Das familiäre Pankreaskarzinomsyndrom [Familial pancreatic cancer syndrome].
    • Seifert L, Weitz J.
    • Chirurgie (Heidelb). 2023 Feb 17. German. doi: 10.1007/s00104-023-01819-8. Epub ahead of print.
    • Review. [Article in German]
    • Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial.
    • Morgan RD, Clamp AR, White DJ, Price M, Burghel GJ, Ryder WDJ, Mahmood RD, Murphy AD, Hasan J, Mitchell CL, Salih Z, Wheeler C, Buckley E, Truelove J, King G, Ainaoui Y, Bhaskar SS, Shaw J, Evans DGR, Kilerci B, Pearce SP, Brady G, Dive C, O'Connor JPB, Wallace AJ, Rothwell DG, Edmondson RJ, Jayson GC.
    • Clin Cancer Res. 2023 Feb 17:CCR-22-3282. doi: 10.1158/1078-0432.CCR-22-3282. Epub ahead of print.

    •• Identifier: NCT02855697: Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer (MOLTO). (ClinicalTrials.gov . Accessed 2023 Feb 18.)

    • Association of FANCM Mutations with Familial and Early-Onset Breast Cancer Risk in a South American Population.
    • Morales-Pison S, Morales-González S, Fernandez-Ramires R, Tapia JC, Maldonado E, Calaf GM, Jara L.
    • Int J Mol Sci. 2023 Feb 17;24(4):4041. doi: 10.3390/ijms24044041.
    • Niraparib Plus Abiraterone/Prednisone Maintains rPFS Benefit in HRR Gene–Altered mCRPC.
    • Wrigley N.
    • OncLive. 2023 Feb 17.

    •• Identifier: NCT03748641: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE). (ClinicalTrials.gov . Accessed 2023 Feb 18.)

    • Defining the heterogeneity of unbalanced structural variation underlying breast cancer susceptibility by nanopore genome sequencing.
    • Dixon K, Shen Y, O'Neill K, Mungall KL, Chan S, Bilobram S, Zhang W, Bezeau M, Sharma A, Fok A, Mungall AJ, Moore R, Bosdet I, Thibodeau ML, Sun S, Yip S, Schrader KA, Jones SJM.
    • Eur J Hum Genet. 2023 Feb 16. doi: 10.1038/s41431-023-01284-1. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Updates in Gynecologic Care for Individuals with Lynch Syndrome.
    • Underkofler KA, Ring K.
    • Front Oncol. 2023 Feb 16;13:1127683. doi: 10.3389/fonc.2023.1127683.
    • Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
    • Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators.
    • N Engl J Med. 2023 Feb 16. doi: 10.1056/NEJMoa2214676. Epub ahead of print.

    •• Identifier: NCT02975934: A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3). (ClinicalTrials.gov . Accessed 2023 Feb 16.)

    • Abiraterone/Olaparib Benefit Is Sustained in Final OS Analysis for mCRPC.
    • Clarke NW, Lovely B.
    • OncLive. 2023 Feb 16.

    •• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2023 Feb 16.)

    • Diagnosis, Management, and Surveillance for Patients with PALB2, CHEK2, and ATM Gene Mutations.
    • Fencer MG, Krupa KA, Bleich GC, Grumet S, Eladoumikdachi FG, Kumar S, Kowzun MJ, Potdevin LB.
    • Clin Breast Cancer. 2023 Feb 15:S1526-8209(23)00034-4. doi: 10.1016/j.clbc.2023.02.004. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Updates in Gynecologic Care for Individuals with Lynch Syndrome.
    • Underkofler KA, Ring K.
    • Front Oncol. 2023 Feb 16;13:1127683. doi: 10.3389/fonc.2023.1127683.
    • Abiraterone/Olaparib Benefit Is Sustained in Final OS Analysis for mCRPC.
    • Clarke NW, Lovely B.
    • OncLive. 2023 Feb 16.

    •• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2023 Feb 16.)

    • Diagnosis, Management, and Surveillance for Patients with PALB2, CHEK2, and ATM Gene Mutations.
    • Fencer MG, Krupa KA, Bleich GC, Grumet S, Eladoumikdachi FG, Kumar S, Kowzun MJ, Potdevin LB.
    • Clin Breast Cancer. 2023 Feb 15:S1526-8209(23)00034-4. doi: 10.1016/j.clbc.2023.02.004. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Prostate cancer and novel pharmacological treatment options - what's new for 2022?
    • Marchetti A, Tassinari E, Rosellini M, Rizzo A, Massari F, Mollica V.
    • Expert Rev Clin Pharmacol. 2023 Feb 15. doi: 10.1080/17512433.2023.2181783. Epub ahead of print.
    • Review
    • Analysis of BRCA1 and BRCA2 alternative splicing in predisposition to ovarian cancer.
    • Jasiak A, Koczkowska M, Stukan M, Wydra D, Biernat W, Izycka-Swieszewska E, Buczkowski K, Eccles MR, Walker L, Wasag B, Ratajska M.
    • Exp Mol Pathol. 2023 Feb 13:104856. doi: 10.1016/j.yexmp.2023.104856. Epub ahead of print.
    • Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review.
    • Hatano K, Nonomura N.
    • World J Mens Health. 2023 Jan 27. doi: 10.5534/wjmh.220200. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Analysis of BRCA1 and BRCA2 alternative splicing in predisposition to ovarian cancer.
    • Jasiak A, Koczkowska M, Stukan M, Wydra D, Biernat W, Izycka-Swieszewska E, Buczkowski K, Eccles MR, Walker L, Wasag B, Ratajska M.
    • Exp Mol Pathol. 2023 Feb 13:104856. doi: 10.1016/j.yexmp.2023.104856. Epub ahead of print.
    • Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review.
    • Hatano K, Nonomura N.
    • World J Mens Health. 2023 Jan 27. doi: 10.5534/wjmh.220200. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Unexpected Findings in Hereditary Breast and Ovarian Cancer Syndrome: Low-Level Constitutional Mosaicism in BRCA2.
    • Mayoral I, Almeida Santiago A, Sánchez-Zapardiel JM, Hidalgo Calero B, de la Hoya M, Gómez-Sanz A, de Miguel Reyes M, Robles L.
    • Genes (Basel). 2023 Feb 15;14(2):502. doi: 10.3390/genes14020502.
    • PARP inhibitor-related hemorrhages:What does the real-world study say?
    • Wang S, Guo M, Fan P, Jin Z.
    • Front Oncol. 2023 Feb 14;13:1070343. doi: 10.3389/fonc.2023.1070343.
    • Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    • Kinney AY, Walters ST, Lin Y, Lu SE, Kim A, Ani J, Heidt E, Le Compte CJG, O'Malley D, Stroup A, Paddock LE, Grumet S, Boyce TW, Toppmeyer DL, McDougall JA.
    • J Clin Oncol. 2023 Feb 14:JCO2200751. doi: 10.1200/JCO.22.00751. Epub ahead of print.

    •• Identifier: NCT03326713: Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project (GRACE). (ClinicalTrials.gov . Accessed 2023 Feb 14.)

    • Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology.
    • Ray T.
    • Precision Oncology News. 2023 Feb 1.
    • News
  • LitAlert ~~ GeneLit.com

    • OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    • Robson ME, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Tung N, Armstrong A, Dymond M, Fielding A, Allen A, Conte P.
    • Eur J Cancer. 2023 Feb 14. doi: 10.1016/j.ejca.2023.01.031. Epub ahead of print.
    • Long-term Data for Niraparib Support Continued Use of PARP Inhibitors in HRD+ Ovarian Cancer.
    • Roque DR, Scott R.
    • OncLive. 2023 Feb 14.
    • Mainstream genetic testing for high-grade ovarian, tubal and peritoneal cancers: A tertiary referral centre experience.
    • Srinivasa S, Bowman M, Titterton L, Harnett P, Brand A, Kirk J, Ragunathan A.
    • Aust N Z J Obstet Gynaecol. 2023 Feb 13. doi: 10.1111/ajo.13650. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • [Expert consensus on the diagnosis and treatment of young breast cancer in China (2022 Edition)].
    • Chinese Society of Clinical Oncology, Experts Committee on Breast Cancer; China Anti-Cancer Association, the Society of Breast Cancer; Chinese Medical Association, Chinese Society of Breast Surgery.
    • Zhonghua Yi Xue Za Zhi. 2023 Feb 14;103(6):387-403. Chinese. doi: 10.3760/cma.j.cn112137-20220907-01895.
    • [Article in Chinese]
    • Preventative Surgeries at Age 32 Because of My BRCA1 Gene Mutation.
    • Clem E.
    • FORCE. Blog. 2023 Feb 13.
    • Women's Metaphors About BRCA Gene Testing and How They Can Inform Health Communication Theory and Practice.
    • Martin SC, Scott AM, Stone AM.
    • Health Commun. 2023 Feb 12:1-13. doi: 10.1080/10410236.2023.2178051. Epub ahead of print.
    • Molecular dynamics simulations reveal the effect of mutations in the RING domains of BRCA1-BARD1 complex and its relevance to the prognosis of breast cancer.
    • Kiewhuo K, Priyadarsinee L, Sarma H, Sastry GN.
    • J Biomol Struct Dyn. 2023 Feb 12:1-19. doi: 10.1080/07391102.2023.2175383. Epub ahead of print.
    • Psychological distress and decision-making factors for prophylactic bilateral mastectomy in cancer-unaffected BRCA1/2 pathogenic variant carriers.
    • Isselhard A, Tüchler A, Dick J, Scherer A, Aue V, Schmutzler RK, Rhiem K.
    • Psychooncology. 2023 Feb 12. doi: 10.1002/pon.6111. Epub ahead of print.
    • Targeting Breast Cancer: An Overlook on Current Strategies.
    • Iacopetta D, Ceramella J, Baldino N, Sinicropi MS, Catalano A.
    • Int J Mol Sci. 2023 Feb 11;24(4):3643. doi: 10.3390/ijms24043643.
    • Challenges in periodic revision of genetic testing results: comparison of the main classification guidelines and report of a retrospective analysis involving BRCA1/BRCA2 Variants of Uncertain Significance.
    • Finger Andreis T, Isabel Weber de Souza K, Araujo Vieira I, Alemar B, Sinigaglia M, Marinho de Araújo Rocha Y, Artigalás O, Bittar C, Brinckmann Oliveira Netto C, Ashton-Prolla P, Rosset C.
    • Gene. 2023 Feb 10:147281. doi: 10.1016/j.gene.2023.147281. Epub ahead of print.
    • A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).
    • Pan E, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Ivy SP, Van Allen EM, Lindeman NI, Kochupurakkal BS, Shapiro GI, McKay RR.
    • Mol Cancer Ther. 2023 Feb 10:MCT-22-0583. doi: 10.1158/1535-7163.MCT-22-0583. Epub ahead of print.
    • Evaluation of AlphaFold Structure-based Protein Stability Prediction on Missense Variations in Cancer.
    • Karakoyun HK, Yuksel SK, Amanoglu I, Naserikhojasteh L, Yakicier C, Yesilyurt A, Timucin E, Akyerli CB.
    • Front Genet. 2023 Feb 8;14:1052383. doi: 10.3389/fgene.2023.1052383.